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Abstract 
We generated T-cell lines from the peripheral blood of controls and of patients with multiple 
sclerosis (MS) by stimulation with overlapping synthetic peptides representing the entire 
sequences of all four isoforms of human myelin basic protein (MBP). The T-cell lines reacted 
to a wide range of epitopes in the major isoforms of MBP and to epitopes that were present 
only in the minor isoforms. Many MS patients and controls had T-cells responding to one or 
more cryptic MBP epitopes, as indicated by the generation of a peptide-specific T-cell line(s) 
by stimulation with synthetic peptides but not by stimulation with whole MBP. About one-
third of the peptide-generated lines were cytotoxic. Although we have shown that this 
technique of peptide stimulation is effective in generating human antiviral cytotoxic CD8+ T-
cell lines, all the cytotoxic MBP-specific lines generated by this method were predominantly 
CD4+. Our study did not reveal any significant differences, between MS patients and controls, 
in reactivity to epitopes within any of the isoforms of MBP.  
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1. Introduction 
There is increasing evidence that multiple sclerosis (MS) is an autoimmune disease (Pender, 
1995) but the target antigens in the central nervous system (CNS) have not been clearly 
determined. Myelin basic protein (MBP) has been implicated as a possible target antigen 
because immunization of experimental animals with MBP and adjuvants results in the disease 
experimental autoimmune encephalomyelitis (EAE), which resembles MS. This form of EAE 
is mediated by CD4+ T-cells specific for MBP (Pettinelli and McFarlin, 1981; Zamvil et al., 
1985). A number of laboratories have isolated MBP-specific T-cell lines or clones from the 
peripheral blood of MS patients and controls by stimulation with whole human MBP (Weber 
and Buurman, 1988; Vandenbark et al., 1989; Martin et al., 1990; Ota et al., 1990; Pette et al., 
1990; Zhang et al., 1990; Liblau et al., 1991; Burns et al., 1991). These lines and clones 
express CD4, are restricted by HLA-DR class II major histocompatibility complex (MHC) 
molecules, and have been analyzed in detail. Little attention has been given to the potential 
role of CD8+ T-cells in the pathogenesis of MS, even though CD8+ cells, as well as CD4+ 
cells, are present in MS lesions (Sobel et al., 1988). Oligodendrocytes, which synthesize MBP 
and other myelin components in the CNS, can be induced to express class I MHC molecules 
(Wong et al., 1984; Turnley et al., 1991) and could thus present MBP to, and be destroyed by, 
cytotoxic CD8+ MBP-specific T-cells. Such oligodendrocyte destruction could contribute to 
the primary demyelination that occurs in MS. 
We therefore performed the present study to determine whether CD8+ MBP-specific T-cells 
could be generated from the peripheral blood of MS patients and controls by stimulation with 
synthetic peptides, using a method we have previously shown to be able to generate human 
antiviral and anti-parasite cytotoxic CD8+ T-cells (Doolan et al., 1991a and Doolan et al., 
1991b). We used overlapping synthetic peptides representing the entire sequence of the most 
abundant isoform (18.5 kDa) of MBP and also the sequences of the 21.5, 20.2 and 17.3 kDa 
isoforms, which are expressed in the developing human CNS (Roth et al., 1987). It has been 
suggested that the minor isoforms may also be expressed by remyelinating oligodendrocytes 
and thus be potential T-cell targets in MS (Voskuhl et al., 1993a and Voskuhl et al., 1993b). 
We also generated T-cell lines by stimulation with whole MBP in order to compare the 
specificities of these lines with those of the lines generated by stimulation with peptides. 
2. Materials and methods 
2.1. Subjects 
Twenty-one patients (12 female; 9 male) aged 17–66 with clinically definite MS or 
laboratory-supported definite MS (Poser et al., 1983) were studied. Seven patients had 
relapsing-remitting MS, 7 had secondary progressive MS and 7 had primary progressive MS. 
The duration of MS ranged from 1–30 years (mean=11±7). The MS patients had not received 
any immunosuppressive or corticosteroid therapy within 6 months prior to study. Twelve 
healthy individuals (4 female; 8 male) aged 24–40 and 2 hospital in-patients (one female, 
aged 47, with Huntington's disease [Con 14], and one female, aged 44, with no evidence of 
neurological disease [Con 13]) served as controls. 
2.2. Myelin proteins and peptides 
MBP was purified from human brain tissue by the method of Deibler et al. (1972), and its 
purity assessed by sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis. 
Overlapping synthetic peptides 20 amino acids in length were synthesized by the tea-bag 
method (Houghten, 1985), using the published sequences of the 18.5 kDa isoform of human 
MBP (Roth et al., 1987). Additional peptides were prepared to represent sequences from the 
deleted and inserted regions in the 21.5, 20.2 and 17.3 kDa isoforms of human MBP. Fig. 1 
shows the 4 human MBP isoforms, and Table 1 lists the synthetic peptides used. Peptides 5B-
5E were synthesized to represent the 26 amino acids in region A. Peptide 10B was made 
according to the sequence of the junctional zone resulting from the deletion of the 11 amino 
acids in region B. All peptides were tested for purity by analytical high-performance liquid 
chromatography (HPLC), and where necessary were further purified by reverse phase HPLC. 
The amino acids were numbered according to their position in the sequence of the 18.5 kDa 
isoform of human MBP.  
 
 
Fig. 1. There are four isoforms of human MBP, arising from alternate exon splicing. The major 18.5 
kDa isoform contains the 11 amino acids (region B) encoded by exon 5, but not the 26 amino acids of 
region A encoded by exon 2. 
 
Table 1. Synthetic peptides 
 
 
Overlapping 20-mer peptides were synthesized to represent the entire sequences of all 4 isoforms of 
human MBP. Peptides 5B-SE cover the 26 amino acids in region A (exon 2) , and peptide 10B covers 
the junctional zone formed by the deletion of 11 amino acids in region B exon 5 see Fig. 1 . For the 
generation of T cell lines, the peptides were pooled into 4 groups, in order to reduce the total number of 
peripheral blood lymphocytes required. 
2.3. Generation of T-cell lines 
Peripheral blood (100 ml) was obtained by venepuncture from each subject. Whole blood was 
centrifuged over a Ficoll-paque gradient (Pharmacia), and peripheral blood mononuclear cells 
(PBMC) were collected from the interface and washed twice with RPMI containing 2 mM -
glutamine, 1% non-essential amino acids, 1 mM sodium pyruvate, 50 U/ml penicillin, 50 
g/ml streptomycin and 10% pooled, heat-inactivated human serum (RPMI-HS). 21 peptides 
covering all isoforms of MBP were pooled into 4 groups (Table 1). Five sets of cultures were 
established from each subject, using 6×106 PBMC for stimulation with each of the 4 groups 
of peptides and 1.2×107 PBMC for stimulation with whole MBP. For the groups of peptides, 
the cells were cultured in duplicate 2 ml wells (3×106 cells per well) in 24-well flat-bottomed 
tissue culture plates (Nunc, Roskilde, Denmark), whereas for whole MBP, the cells were 
cultured in quadruplicate 2 ml wells (3×106 cells per well). Every 10–12 days each line was 
restimulated with the appropriate group of peptides (each peptide at a concentration of 30 
g/ml) and irradiated autologous phytohaemagglutinin-activated lymphoblasts (for peptide-
generated lines, as described by Doolan et al. (1991b)), or MBP (30 g/ml) and irradiated 
autologous PBMC (for MBP-generated lines), followed by feeding with RPMI-HS containing 
10 U/ml recombinant human IL-2. After 4–5 weeks, the lines were tested for their 
proliferative and cytotoxic specificity. 
2.4. Assessment of T-cell line proliferative specificity 
To test the specificity of the T-cell lines, 104 T-cells were incubated with 105 irradiated 
autologous PBMC and MBP peptide or whole MBP (30 g/ml) in a total volume of 200 l. 
The experiments were performed in triplicate in 96-well round-bottomed microtitre tissue 
culture plates (Nunc) for 72 h. During the final 12 h of culture, 1 Ci of 3H-thymidine 
(Amersham Australia, Sydney) was added to each well. Cells were harvested onto glass fibre 
filter mats, and the amount of incorporated radioactive label was determined by scintillation 
counting using an LKB 1205 Betaplate liquid scintillation counter. The stimulation index (SI) 
was then determined for each mixture of cells and peptide or MBP. The SI was defined as the 
ratio of the mean cpm of test cultures (with added peptide or whole MBP) and the mean cpm 
of control cultures (no added peptide or MBP). A positive antigen-specific proliferative 
response was taken as one in which the SI was greater than or equal to 2 and in which the 
mean cpm of test cultures exceeded the mean cpm of control cultures by 3 SD of the control 
mean. 
2.5. Assessment of T-cell line cytotoxic capacity 
T-cell lines showing positive proliferative responses were assessed for cytotoxic capacity by 
standard 6 h chromium release assays, using, as targets, autologous Epstein-Barr virus (EBV)-
transformed lymphoblastoid cell lines (LCLs) that had been incubated overnight with grouped 
peptides (each peptide at a concentration of 10 g/ml), individual peptides (10 g/ml) or 
MBP (10 g/ml). The effector/target ratio was 10:1. Prior to the assay the LCL cells were 
washed, labelled for 90 min with 200 Ci of 51Cr(Na2Cr3O4) at 37°C, and then washed 4 more 
times with medium. Labelled target cells were plated at 5×103 cells/well in 96-well round-
bottomed plates, and effector T-cells were mixed and incubated with these as triplicate 
cultures in 200 l volumes for 6 h at 37°C in the presence and in the absence of grouped 
peptides (each peptide at a concentration of 5 g/ml), individual peptides (5 g/ml) or MBP 
(5 g/ml). Maximum release and spontaneous release of chromium label were measured in 
wells containing target cells in the presence of 10% SDS or medium alone respectively. Fifty 
l of supernatant was removed from each well after 6 h and counted in a gamma counter. The 
assays were performed with test T-cells and target LCL cells in the presence of free peptide 
(peptide lysis) and in the absence of peptide (control lysis). Percentage peptide-specific lysis 
was calculated by the formula: 
 
 
Results for both peptide and control lysis assays were calculated using the following formula: 
 
 
Assays were only considered valid if spontaneous release was less than 20% of maximum 
release. A peptide-specific lysis>10% was considered to indicate antigen-specific cytotoxic 
capacity (Doolan et al., 1991b). 
2.6. Flow cytometry analysis 
All cytotoxic and some non-cytotoxic T-cell lines were analyzed for CD4 and CD8 
expression. Cells (5×105) were washed in ice-cold phosphate-buffered saline supplemented 
with 1% foetal calf serum and 0.01% NaN3, split into 3 tubes, and resuspended in 100 l 
volumes. Directly conjugated (fluorescein isothiocyanate) anti-human-CD4 or -CD8 
antibodies (Becton Dickinson, Belgium) were added to the cell suspension and incubated for 
30 min at 4°C. Cells were subsequently washed twice and analyzed on a FACScan (Becton 
Dickinson) with gates set to include the total population. 
2.7. DR tissue typing 
Genomic DNA was prepared from donor LCLs by chloroform/phenol extraction and 
amplified by the polymerase chain reaction (PCR) using 5 generic primer pairs. One pair 
amplifies the second exon of all the DRB genes, and one pair is used to amplify each of the 
DR1, DR2, DR4, and DRw52 allelic groups. The PCR product was then quantified on an 
agarose gel before denaturation with NaOH/EDTA, and dot blotted onto a positively charged 
membrane. Membrane-bound DNA was hybridized sequentially using a panel of 45 
sequence-specific oligonucleotides. Hybridization signal was detected using non-radioactive 
techniques and the hybridization patterns analyzed, enabling the individual DRB1 alleles to 
be assigned. 
2.8. Statistical analysis 
The percentage of subjects from whom T-cell lines reactive to a given peptide could be 
generated was compared in MS patients and controls using the Chi-square test with Yates' 
correction applied as required. 
3. Results 
3.1. Generation of T-cell lines by stimulation with whole MBP 
By stimulation with whole MBP, 8 T-cell lines were derived from the peripheral blood of 14 
controls (Fig. 2), and 10 lines were derived from the blood of 20 patients with MS (Fig. 3). 
The most frequent immunodominant peptides were peptides 9 (82–100), 14 (131–150) and 15 
(141–160), but other peptides, particularly 1 (1–20), 7 (61–80) and 13 (122–140), were 
immunodominant in some subjects (Fig. 4). There were no significant differences, between 
MS patients and controls, in the reactivities of the lines. The reactivities of the T-cell lines 
from the MS patients to peptides 82–100, 131–150 and 141–160 did not correlate with 
expression of the MS-associated DRB1*1501 allele (Hillert, 1994). Two of the lines from the 
controls (Fig. 2) and 3 of the lines from MS patients were cytotoxic (Fig. 3). The levels of 
cytotoxicity of a line from a control (Con 11) and of a line from an MS patient (MS 21) are 
shown in Fig. 5A and 5B respectively. Interestingly, the line from MS 21 exhibited 
cytotoxicity towards at least 3 different MBP epitopes (peptides 7, 9 and 14/15). All of the 
cytotoxic lines from controls and MS patients, and all 4 of the analyzed non-cytotoxic lines 
derived from MS patients were predominantly CD4+ (mean=85±7%; range 71–98%); none 
was predominantly CD8+ (mean=10±5%; range 3–20%).  
 Fig. 2. Whole-MBP-generated T-cell lines from each control were tested for proliferative and cytotoxic 
responses to whole MBP and to individual peptides. Positive proliferative responses (stimulation 
index≥2) are shown as black rectangles. T-cell lines showing both positive proliferative responses and 





Fig. 3. Whole-MBP-generated T-cell lines from each patient with MS were tested for proliferative and 
cytotoxic responses to MBP and to individual peptides, as in Fig. 2. 
 
 
Fig. 4. Percentages of subjects (controls, open bars; MS patients, closed bars) from whom T-cell lines 





Fig. 5. Peptide-specific lysis (%) by T-cell lines generated by stimulation with whole MBP. Panel A 
shows the results for a line generated from a control subject (Con 11), and panel B for a line generated 
from a patient with MS (MS 21). The lines were first tested against the groups (Gr1–4) of peptides and 
against MBP. If a positive cytotoxic response (>10% peptide-specific lysis) against a particular group 
was found, the line was tested against the individual peptides within that group and again tested against 
the whole group. 
 
3.2. Generation of T-cell lines by stimulation with synthetic MBP 
peptides 
By stimulation with the four groups of synthetic MBP peptides, 30 T-cell lines were derived 
from the peripheral blood of 14 controls (Fig. 6), and 48 lines were derived from the blood of 
19 patients with MS (Fig. 7). The specificities of the lines were diverse, and each of the 21 
peptides was recognized by at least one T-cell line. The lines most commonly reacted to 
peptides 1 (1–20), 5E (C-terminal region of exon-2-encoded segment), 9 (82–100), 11 (101–
120), 14 (131–150) and 15 (141–160) (Fig. 8). Many MS patients and controls had T-cells 
responding to one or more cryptic MBP epitopes, as indicated by the generation of a peptide-
specific T-cell line(s) by stimulation with synthetic peptides but not by stimulation with 
whole MBP (compare Fig. 6 with Fig. 2, and Fig. 7 with Fig. 3). Some of these peptide-
generated lines responded to whole MBP as well as to peptide, for example: Con 2, peptide 5; 
Con 3, peptide 15; Con 5, peptide 2; Con 7, peptide 2; Con 7, peptide 14; MS 11, peptide 11; 
MS 15, peptide 1; MS 20, peptide 10B. There were no differences, between MS patients and 
controls, in the reactivities of the lines, except for a higher frequency of lines reactive to 
peptide 9 (82–100) in the patients with MS, which was not statistically significant. Six of 9 
tissue-typed MS patients with T-cell lines reactive to the 82–100 peptide expressed 
DRB1*1501; however, 5 of 7 tissue-typed MS patients without such lines also expressed this 
allele. One patient with T-cells reactive to this peptide expressed DRB1*1502. Thirty % of the 
lines derived from controls (Fig. 6) and 37.5% of those derived from MS patients were 
cytotoxic (Fig. 7). The levels of cytotoxicity of lines from a control (Con 11) and from an MS 
patient (MS 13) are shown in Fig. 9A and 9B, respectively. In some cases a T-cell line was 
found to show cytotoxicity towards the whole group of peptides with which it was generated, 
but could not be found to demonstrate a positive cytotoxic response against any individual 
peptide within that group (for example, Fig. 9A, T2). This might be explained by low levels 
of cytotoxicity against several individual peptides within the group. All the cytotoxic T-cell 
lines generated from controls and MS patients were predominantly CD4+ (mean=84±8%; 
range 64–97%); none was predominantly CD8+ (mean=11±5%; range 1–22%).  
 
Fig. 6. T-cell lines were generated from each control by stimulation with each of the four groups (Gr1–
4) of synthetic peptides. These lines (T1–T4) were tested for proliferative and cytotoxic responses 
against the whole groups of peptides, peptides within each group and MBP. Positive proliferative 
responses (stimulation index≥2) are shown as black rectangles. T-cell lines showing both positive 
proliferative responses and positive cytotoxic responses (>10% peptide-specific lysis) to a given group 
of peptides, to an individual peptide or to MBP are designated by black ovals. 
  
 
Fig. 7. T-cell lines were generated from each patient with MS by stimulation with each of the four 
groups (Gr1–4) of synthetic peptides. These lines (T1–T4) were tested for proliferative and cytotoxic 
responses as in Fig. 6. A black diamond indicates a positive cytotoxic response in the absence of a 
positive proliferative response. 
 
Fig. 8. Percentages of subjects (controls, open bars; MS patients, closed bars) from whom T-cell lines 
of different specificities (stimulation index≥2) could be successfully generated by stimulation with 






Fig. 9. Peptide-specific lysis (%) by T-cell lines generated by stimulation with groups (Gr1–4) of 
synthetic MBP peptides. Panel A shows the results for the 3 lines (T2, T3 and T4) generated from a 
control subject (Con 11), and panel B shows the results for the 2 lines (T2 and T3) generated from a 
patient with MS (MS 13). Each line was tested against the group of peptides with which it was 
generated and against the individual peptides within that group, as well as against whole MBP. 
To confirm the ability of the technique to induce and maintain the growth of CD8+ cytotoxic 
T-cell lines, a peptide from EBV nuclear antigen 3 (residues 329–353) (Burrows et al., 1990) 
was used to stimulate repetitively PBMC from an HLA-B8+ healthy subject, as previously 
described (Doolan et al., 1991b). This resulted in the generation of a CD8+ T-cell line that 
induced 31% peptide-specific lysis of autologous target LCLs at an effector/target ratio of 
10:1 (not shown). 
4. Discussion 
In the present study we investigated whether CD8+ MBP-specific T-cells could be generated 
from MS patients and controls, using a method we have previously shown to be able to 
generate human antiviral and anti-parasite CD8+ cytotoxic T-cells (Doolan et al., 1991a and 
Doolan et al., 1991b). With this technique we developed 78 T-cell lines reactive to one or 
more of 21 overlapping synthetic peptides representing the total lengths of the four isoforms 
of human MBP. 27 of these lines were cytotoxic. All of the cytotoxic lines were 
predominantly CD4+ and none was predominantly CD8+. Using techniques similar to ours, 
other workers have shown that CD8+ MBP-specific T-cell lines can occasionally be derived 
from MS patients and healthy individuals (Inobe et al., 1993; Tsuchida et al., 1994). Tsuchida 
et al. (1994) were able to generate CD8+ T-cell lines reactive to the 110–118 peptide of MBP 
from 1 of 10 HLA-A2+ normal individuals and 1 of 9 HLA-A2+ MS patients, after using a 
computer-based algorithm to predict that this peptide would bind to HLA-A2. One possible 
explanation for our findings is that the 20-residue peptides bound to MHC class II molecules 
better than to MHC class I molecules and hence favoured antigen presentation to CD4+ T-
cells rather than to CD8+ T-cells. However, our results suggest that the MBP-reactive T-cell 
repertoire in MS patients and controls is strongly biased towards CD4+ T-cells. 
Generally the number of epitopes recognized by peptide-generated T-cell lines from an 
individual subject was greater than the number recognized by T-cell lines generated by 
stimulation with whole MBP, although there were occasional subjects from whom no specific 
lines could be generated by either method of stimulation. Many MS patients and controls had 
T-cells responding to one or more cryptic MBP epitopes, as indicated by the generation of a 
peptide-specific T-cell line(s) by stimulation with synthetic peptides but not by stimulation 
with whole MBP. The more effective generation of lines by stimulation with peptides is 
explained by the circumvention of the need for antigen processing, as the synthetic peptides 
can bind directly to MHC molecules on the antigen-presenting cells. The spectrum of MBP 
epitopes recognized by the peptide-generated lines was diverse, which is consistent with the 
finding in the Lewis rat of a wide range of cryptic encephalitogenic MBP epitopes (Mor and 
Cohen, 1995). 
Using the method of peptide stimulation we were also able to generate T-cell lines reactive to 
epitopes present in the minor 21.5 kDa and 20.2 kDa isoforms of human MBP (in the exon-2-
encoded region) but not present in the common 18.5 kDa isoform. Such lines could be 
generated from both MS patients and controls, as previously reported by Voskuhl et al. 
(1993a) and Voskuhl et al. (1993b). We were also able to generate, from 2 MS patients, T-cell 
lines reactive to a novel MBP epitope (peptide 10B) present in the 20.2 and 17.3 kDa 
isoforms but not in the 21.5 or 18.5 kDa isoforms. As the 21.5, 20.2 and 17.3 kDa isoforms 
are expressed in the developing human CNS (Roth et al., 1987), it has been suggested that 
they may also be expressed by remyelinating oligodendrocytes in MS lesions (Voskuhl et al., 
1993a). 
We found that the most common immunodominant epitopes revealed by generation of T-cell 
lines by stimulation with whole MBP were within the 82–100 and 131–160 regions, as 
previously reported by others (Martin et al., 1990; Ota et al., 1990; Zhang et al., 1990 and 
Zhang et al., 1992; Liblau et al., 1991). However, we also found that other regions, 
particularly 1–20, 61–80 and 122–140, contained immunodominant epitopes in some MS 
patients and healthy individuals. 
Our study did not reveal any significant differences between MS patients and controls in 
reactivity to MBP epitopes within any of the isoforms of MBP. However, this does not rule 
out a role for MBP-specific T-cells in the pathogenesis of MS, as differences in activation 
status or cytokine production would not have been detected by our methods.  
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